Literature DB >> 10570552

The caseload, assessment and treatment of atopic dermatitis: a survey of Australian dermatologists.

R B Stephens1, A Cooper.   

Abstract

In early 1995 we surveyed all 250 practicing Australian members of the Australasian College of Dermatologists by a mail-out questionnaire to determine information, such as the caseload imposed by atopic dermatitis, the severity of cases seen by dermatologists, current treatment and dermatologists' satisfaction with treatment. One hundred and forty-nine responses were received. Fifty per cent of patients with atopic dermatitis seen by dermatologists were younger than 10 years, 18% were 10-16 years, and 52% were older than 16 years. Disease was considered to be severe in 18% of patients, moderate in 41% and mild in 41%. Emollients and topical corticosteroids were the most commonly used treatments but there was wide variation in other treatments used by individual dermatologists. Only 10% of respondents were very satisfied with existing treatments for severe atopic dermatitis; 20% of patients with severe disease were considered as refractory or non-responsive. New therapies such as cyclosporin have the potential to improve existing standards of care.

Entities:  

Mesh:

Year:  1999        PMID: 10570552     DOI: 10.1046/j.1440-0960.1999.00357.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  2 in total

1.  'Not just a piece of skin in front of you'-a qualitative exploration of the experiences of adolescents with eczema and psoriasis with healthcare professionals.

Authors:  Isabella Joy de Vere Hunt; Abigail McNiven; Amanda Roberts; Himesh Parmar; Tess McPherson
Journal:  BMJ Open       Date:  2021-01-29       Impact factor: 2.692

2.  Impact of interactive web-based education with mobile and email-based support of general practitioners on treatment and referral patterns of patients with atopic dermatitis: randomized controlled trial.

Authors:  Thomas Schopf; Vibeke Flytkjaer
Journal:  J Med Internet Res       Date:  2012-12-05       Impact factor: 5.428

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.